REPLIGEN CORP Interest Income (Expense), Nonoperating, Net
REPLIGEN CORP (RGEN) reported Interest Income (Expense), Nonoperating, Net of -$11.70 thousand for the 3-month period ending 2013-09-30, per its 10-Q filed 2013-11-08.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2013-11-08
- REPLIGEN CORP interest income (expense), nonoperating, net for the quarter ending 2013-09-30 was -$11.70K, a 262.44% decline year-over-year.
- REPLIGEN CORP interest income (expense), nonoperating, net for the quarter ending 2012-09-30 was $7.21K.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 9 month |
|---|---|---|
| 2013-09-30 | -$11.70K 10-Q · filed 2013-11-08 | -$37.64K 10-Q · filed 2013-11-08 |
| 2012-09-30 | $7.21K 10-Q · filed 2013-11-08 | -$42.54K 10-Q · filed 2013-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |